Upadacitinib 15mg modified-release tablets
NHS hospitals in England used £78,630,918 of indicative cost of Upadacitinib 15mg modified-release tablets in the 12 months to July 2026, about 0.3% of all hospital medicines spend. That is up 27.3% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Upadacitinib 15mg modified-release tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Upadacitinib 15mg modified-release tablets most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Royal Devon & Exeter Nhs Foundation Trst | £2,833,787 |
| Sussex Community Nhs Foundation Trust | £2,800,127 |
| Cambridge Univ Hosp Nhs Foundation Trust | £2,126,678 |
| Luton & Dunstable Hospital Trust | £1,938,983 |
| Northampton General Hosp Trust | £1,882,594 |
| Derby Teaching Hospitals Nhs Found Trust | £1,759,631 |
| University Hpls Of Leicester Nhs Trust | £1,668,430 |
| Leeds Teaching Hpls Nhs Trust | £1,610,631 |
| Western Sussex Hospitals Nhs Found Trust | £1,481,425 |
| Manchester University Nhs Ft | £1,475,124 |
The primary-care picture
Upadacitinib is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Upadacitinib medicine page.